Today we announced our 2024 Full Year Results. Join us at 9AM EDT / 2PM GMT for a live webcast as our management team discusses our strong clinical, operational, and financial progress throughout 2024 and into early 2025. bit.ly/3GwtB29

We’re heading to #ATS2025! Don't miss our late-breaking oral presentation of our Ph2b ELEVATE IPF trial of deupirfenidone (LYT-100), highlighting its potential to stabilize lung function decline over 26 weeks w/ favorable tolerability in patients w/ #idiopathicpulmonaryfibrosis

We’re proud to share new research in BMC Pulmonary Medicine (BMC) that captures the real-world experiences of people living with #idiopathicpulmonaryfibrosis. Conducted with #IPF experts & @PFForg, it highlights gaps in diagnosis, treatment options, and quality of

We’re presenting new data from our Phase 2b ELEVATE #IPF trial today at 2:15pm PT at #ATS2025! The results reinforce deupirfenidone’s potential to deliver meaningful efficacy with favorable tolerability — and to set a new standard of care for people living with IPF. Hope to see

Just presented at #ATS2025: New preliminary 52-week open-label extension data from our Phase 2b ELEVATE #IPF trial reinforce deupirfenidone’s strong and durable efficacy — slowing lung function decline to the range expected in healthy older adults, with favorable tolerability.

Our CEO, Bharatt Chowrira, Ph.D., J.D., and Co-founder and President, Eric Elenko, Ph.D., will participate in a fireside chat at the #JefferiesHealthcare Conference on Thursday, June 5th, at 10:30am EDT bit.ly/3YVdEZC

At the #JefferiesHealthcare Conference, our CEO, Bharatt Chowrira, Ph.D., J.D., and Co-founder and President, Eric Elenko, Ph.D., discussed our value-driving portfolio, capital-efficient model, and the compelling case for deupirfenidone in #IPF Watch the full replay here:

How do #raredisease companies overcome the economic challenges of drug development, especially in today’s policy and funding landscape? Join us at #BIO2025 as Dr. Camilla Graham, SVP of Medical Affairs, and a cross-sector panel explore this critical question.

Today, we commemorate #Juneteenth and reflect on its significance in the ongoing pursuit of freedom, equity, and justice—and the responsibility we all share in advancing it. At PureTech, giving life to science means fostering a culture rooted in respect, inclusion, and shared

This #IndependenceDay, we’re celebrating the spirit of innovation that drives scientific progress and the freedom to pursue bold ideas that can change lives. As the birthplace of biotech, the United States has fostered a culture of entrepreneurship, risk-taking, and a belief

Today we announced that Robert Lyne has been appointed Interim Chief Executive Officer of PureTech. Rob previously served as our Chief Portfolio Officer and is an experienced leader of UK-listed life science companies. Rob succeeds Bharatt Chowrira, PhD, JD, who has stepped down

Pleased to announce the first patient has been dosed in our Ph2b BUOY-1 study of GlyphAllo™ (SPT-300) in #MDD w/ or w/o anxious distress, an important milestone for Seaport’s pipeline that brings us closer to a potential new treatment for patients w/ MDD: bit.ly/3Uhn3YB

Last week, we helped Cradles to Crayons prep for their annual BackPack-A-Thon, unboxing & organizing thousands of school supplies at Boston University’s Agganis Arena. These efforts provide 75,000 local students with essentials to start the school year. At PureTech, we’re

We’re proud to announce the launch of Celea Therapeutics, a new PureTech Founded Entity dedicated to transforming the treatment of serious respiratory diseases. Celea’s lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate with the potential to set a

At the 2025 IPF Summit, PureTech showcased how we’re pairing compelling data with deep patient insights and innovative trial design to advance deupirfenidone (LYT-100) as a potential new standard of care in #idiopathicpulmonaryfibrosis. From the strength of our Phase 2b ELEVATE

Today we announced our 2025 Half-Year results & will host a webcast at 9am EDT/2pm BST. We continue to give life to science while transforming innovation into value through our hub-and-spoke model. Read more: bit.ly/41ulOJQ

Congrats to our Founded Entity SeaportTx on advancing its second candidate into the clinic!

Our team is proud to participate in the Pulmonary Fibrosis Foundation’s National Walk Day in honor of the passionate community driving advances in idiopathic pulmonary fibrosis (#IPF) care: patients, caregivers, physicians, advocates, and researchers working to develop new

We’re proud to share new data at #ERS2025 from our Phase 2b ELEVATE IPF OLE. The data show that patients w/ #IPF who switched from placebo or pirfenidone to deupirfenidone achieved lung function stabilization w/ favorable tolerability. #ERSCongress ERS